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Genome-wide proﬁling of p53-regulated enhancer
RNAs uncovers a subset of enhancers controlled by
a lncRNA
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p53 binds enhancers to regulate key target genes. Here, we globally mapped p53-regulated
enhancers by looking at enhancer RNA (eRNA) production. Intriguingly, while many p53-
induced enhancers contained p53-binding sites, most did not. As long non-coding RNAs
(lncRNAs) are prominent regulators of chromatin dynamics, we hypothesized that p53-
induced lncRNAs contribute to the activation of enhancers by p53. Among p53-induced
lncRNAs, we identiﬁed LED and demonstrate that its suppression attenuates p53 function.
Chromatin-binding and eRNA expression analyses show that LED associates with and acti-
vates strong enhancers. One prominent target of LED was located at an enhancer region
within CDKN1A gene, a potent p53-responsive cell cycle inhibitor. LED knockdown reduces
CDKN1A enhancer induction and activity, and cell cycle arrest following p53 activation.
Finally, promoter-associated hypermethylation analysis shows silencing of LED in human
tumours. Thus, our study identiﬁes a new layer of complexity in the p53 pathway and
suggests its dysregulation in cancer.
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F
or several decades the foundations of molecular biology
leaned against the dogma that genetic information is stored
in protein-coding genes1. Although this concept was, and is
still, largely true in prokaryotes, where genomes are mainly
composed of protein-coding genes, it does not hold true for
higher eukaryotes, where protein-coding sequences occupy less
than 3% of the genome. Once considered transcriptionally
inactive or simply referred to as ‘junk DNA’, the predominant
fraction of the genome is in fact pervasively transcribed into
thousands of different noncoding RNAs (ncRNAs), which can
further be divided into two groups: small ncRNAs and long
noncoding RNAs (lncRNAs). In addition, lncRNA genes have
been classiﬁed based on the epigenetic state of their chromatin.
For instance, the long intergenic noncoding RNAs (lincRNAs)
are known for the presence of high histone 3 lysine 4
trimethylation (H3K4me3) at their promoters and high
H3K36me3 along their transcribed regions, also referred as the
K4K36 signature2. Alternatively, enhancer RNAs (eRNAs) are
produced from transcriptionally active enhancer regions,
which are epigenetically deﬁned by high level of H3K4me1, low
level of H3K4me3 (refs 3,4) and high level of histone 3 lysine 27
acetylation (H3K27Ac) and H3K9Ac5.
Importantly, lincRNAs have recently emerged as potent
regulators of gene expression. Recent publications have shown
that lincRNAs are able to form complexes with various chromatin
modiﬁers and to speciﬁcally direct them to different genomic
regions. For example, the lincRNA-p21 was shown to interact
with and guide the heterogeneous nuclear ribonucleoprotein K to
repress a subset of p53 target genes6. However, although
lincRNAs can mediate their effect in cis and in trans, eRNAs
have been so far mainly characterized for their function in cis.
Classically expressed as bidirectional transcripts from enhancer
regions, eRNAs can alter the expression of their neighbouring
genes through the formation of DNA loops, which help to bridge
the interaction between enhancers and nearby promoters. Several
transcription factors (TFs) were found to be important
coordinators of eRNA expression7–9. An interesting case
revealed that the tumour-suppressor p53 directly regulates the
expression of eRNAs upon cellular stresses9.
P53 function is frequently compromised in tumours, in part as
a consequence of somatic mutations, which occur in more
than 50% of all human cancers10. Moreover, it was also shown
that p53 is inactivated in various cancers by dysregulation of its
regulatory pathway, such as the ampliﬁcation and over-
expression of its negative regulators MDM2 and MDM4
(refs 11,12). Upon cellular stresses, p53 is activated and acts
primarily as a TF to mediate and coordinate a complex
transcriptional response that regulates hundreds of target genes.
Until recently, the p53 network was mainly characterized
by its impact on protein-coding target genes13. However, we
now begin to discover and appreciate the great potential of
ncRNAs in the intricate regulatory network of p53. The recent
discoveries that p53 can mediate its function in collaboration
with diverse lncRNAs, suggest a potential role for this novel
regulatory layer in disease such as cancer, and therefore urge the
importance of an in-depth reassessment of the p53 transcriptional
response.
Here, by using Global Run-On sequencing (GRO-seq), we
mapped p53-responsive enhancers bound by p53. Surprisingly,
we also found a large group of p53-activated enhancers that were
not associated with p53. Although motif-search analysis identiﬁed
the p53 signature in the enhancers bound by p53, no single TF
was found to govern the majority of p53-unbound enhancer
groups. However, further analysis revealed that nutlin-3a-induced
Signal transducer and activator of transcription 3 (STAT3), B-cell
lymphoma 3-encoded protein (BCL3), FBJ murine osteosarcoma
viral oncogene homolog (FOS) might largely contribute to the
transcriptional regulation of indirect p53 target genes. Next, we
assessed whether p53-responsive lncRNAs could play a role in
p53-mediated enhancer activation. Our data revealed that a
prominent p53-induced lncRNA termed LED (LncRNA activator
of Enhancer Domains) is required for p53-induced cell cycle
arrest and is involved in the activation of a subset of p53-bound
and unbound enhancers by inducing an epigenetic change.
Strikingly, promoter-associated hypermethylation of LED was
uncovered in several cancer cell lines and human tumours with
preference to p53 wild-type (WT) status, suggesting its implica-
tion in tumorigenesis. Altogether, we propose that LED is an
important regulator and a potential tumour suppressor of the p53
pathway.
Results
Genome-wide identiﬁcation of p53-regulated eRNAs. To detect
active enhancers, we relied on the observation that eRNA pro-
duction marks enhancer activity. Using GRO-seq of MCF-7 cells
treated with nutlin-3a, a speciﬁc activator of p53, we obtained a
genome-wide quantitative snapshot of transcriptional activity. As
expected, the activation of CDKN1A/p21, and many other known
target genes of p53, was readily apparent (Fig. 1a). Moreover,
also several previously described p53-induced eRNAs could be
conﬁrmed (Fig. 1a)9. We proceeded to generate a global view of
the putative p53-regulated enhancers in MCF-7 cells. By taking
the union of the enhancer domains deﬁned by the Broad
chromatin segmentation14, we selected only regions showing
RNA polymerase II (RNAPII) and p300 binding in MCF-7
cells (using publicly available chromatin immunoprecipitation
sequencing (ChIP-seq) data15) and excluded those having
Figure 1 | Identiﬁcation of p53-regulated enhancer RNAs (p53RERs). (a) GRO-Seq snapshot showing the induction of CDKN1A/p21 transcription upon
12 h nutlin-3a treatment (upper scheme). Display of nutlin-3a-induced bidirectional transcription at p53-bound and unbound enhancers (lower schemes).
Binding of p300, presence of H3K27 acetylation and chromatin states in nine cell lines are also presented. (b) Diagram showing the outline of the algorithm
to identify enhancers using chromatin segmentation data, and ChIP-Seq and GRO-Seq data. (c) Venn diagram showing the number of retrieved regions at
the steps of the enhancer identiﬁcation algorithm. (d) Boxplot showing the abundance of several enhancer marks at different regions (grey: 5,000 random
non-repeat regions; red: promoters of the 5,000 most abundant genes as identiﬁed by GRO-seq in the nutlin-3a-treated condition; orange: all putative
enhancer regions showing bidirectional transcription; blue: subset of the putative enhancers showing signiﬁcant induction upon nutlin-3a treatment
(induced p53RERs); dark blue: subset of the induced p53RERs having a p53 peak within 1 kb (p53BERs). (e) Boxplot showing the distances between
enhancer region and the nearest annotated gene induced upon nutlin-3a treatment, for induced p53RERs (UP Enhancers) and nutlin-3a unresponsive
enhancers (nonUP enhancers). (f) Motif identiﬁed in induced p53BERs using HOMER. (g) Normalized density of transcription downstream of the point of
bidirectional transcription for p53BERs (red), p53FERs (dark grey) and uninduced enhancers (light grey). The lines indicate the median across all regions.
The boxplot in the inset shows the distance from the point of bidirectional transcription to the 75% quantile of read density. (h) Schematic representation
of p53-regulated enhancers (p53RERs). P53 can directly bind to enhancers (p53BERs) or regulated intermediate factors (for example, lncRNAs or TFs) to
indirectly inﬂuence another subset of enhancers (p53FERs).
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annotated transcripts on both strands, as well as those having
transcription start sites. The remaining regions were extended by
1 kb for the purpose of read counting and used in conjunction
with the aforementioned GRO-seq data (Fig. 1b). This analysis
resulted in the detection of 50,502 putative enhancers of which
6,270 were regulated (at least one direction) by nutlin-3a
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treatment, and referred here as p53-regulated enhancer regions or
p53RERs.
Since p53 mainly functions as an activator of transcription16, the
vast majority (72%) of the differentially expressed eRNAs showed
induction upon nutlin-3a treatment, and activated enhancers were
more often bound by p53 than the repressed enhancers (Fig. 1c).
Using ENCODE ChIP-seq data obtained from MCF-7 cells, the
presence of enhancer-speciﬁc histone modiﬁcations was conﬁrmed
(Fig. 1d). Moreover, on average, nutlin-3a-induced enhancers are
positioned closer to p53-regulated canonical genes (median 41 kb),
than to non-regulated genes (median 161 kb; Fig. 1e). This
observation is in agreement with the notion that eRNAs are
potent regulators of neighbouring target genes7–9. In support of a
role for nutlin-3a-regulated enhancer regions within the p53
pathway, the gene ontology analysis on neighbouring genes
revealed enrichment for genes involved in DNA damage
response/signal transduction by p53 (GO term 0030330,
P¼ 1.6e 3). Moreover, a de novo motif analysis using
HOMER17 conﬁrmed the presence of a p53 response element at
p53-bound enhancer regions (p53BERs; Fig. 1f).
Next we reanalysed published p53 ChIP-seq data15 to identify
which of the p53RERs were direct targets of p53 (hereafter
referred to as p53BERs). The enhancers in the remaining subset
of p53RERs were considered p53-free enhancer regions, or
p53FERs, as no enrichment for p53 or any known TF signature
was found. Intriguingly, activation of p53BERs and p53FERs was
different, as we observed a faster transcription drop-off for the
ﬁrst group compared with the second (Fig. 1g and Supplementary
Fig. 1a). Although we did not further investigate this difference,
we suggest that it reﬂects a secondary (p53-indirect) and, thus,
differentially regulated wave of transcription (Supplementary
Fig. 1b). Therefore, we hypothesized that activation of p53FERs
could be mediated by a combination of several different factors
(Fig. 1h). Indeed, the analysis of TF-binding sites (using the
ENCODE Uniform TFBS data) showed that while several TFBSs
were enriched in induced p53RERs, with respect to all enhancers,
no TFBS was speciﬁcally enriched in the p53-free enhancer group
(Supplementary Fig. 1c). However, further analysis revealed that
among these potential regulators, three (STAT3, BCL3 and FOS)
were regulated by nutlin-3a (Supplementary Fig. 1d,e).
Intersection between their binding sites and p53FERs revealed
that STAT3, BCL3 and FOS may directly regulate 55% of these
enhancer regions (Supplementary Fig. 1f). Interestingly, despite
their signiﬁcant contribution, the transcriptional regulation of a
large number of p53FERs remains elusive. An additional or
complementary possibility is that the transcriptional activation of
enhancers is mediated by p53-dependent lncRNAs, as lncRNAs
were recently shown to be able to associate with and modulate
regulatory elements18,19.
LED is required for the p53 transcriptional response. We
therefore set to identify relevant lncRNAs by proﬁling the
transcriptome of nutlin-3a-treated MCF-7 cells. Using RNA-
sequencing (RNA-seq) in combination with an annotation
catalogue comprised of Ensembl, Refseq and the Broad Linc
Catalog20, we identiﬁed 194 nutlin-3a-responsive lncRNA genes
(Fig. 2a and Supplementary data 1). We then reasoned
that the most upregulated transcripts might have a greater
biological importance, and consequently selected the top three
most activated lncRNAs (that is, RP3-510D11.2, loc643401 and
linc00086 (hereinafter referred to as LED)) for further
characterization (Fig. 2b). Interestingly, these three lncRNAs
were also recently identiﬁed, but not functionally assessed, in two
genome-wide studies performed in HCT-116 and Cal-51 cancer
cell lines21,22. Validation conﬁrmed that the selected lncRNAs
were induced in MCF-7 cells upon both nutlin-3a and ionizing
radiation treatment (Fig. 2c). Similar results were also obtained in
ZR-75-1 and MALM-3M cell lines (Supplementary Fig. 2a). Next,
we determined whether these lncRNAs were regulated by p53. As
expected, we observed that p53 depletion decreased both the basal
and nutlin-3a-induced levels of all tested lncRNAs (Fig. 2d).
Moreover, we demonstrated the direct binding of p53 at each
lncRNA locus by using publicly available p53 ChIP-seq data and
ChIP-quantitative PCR (qPCR; Fig. 2e and Supplementary
Fig. 2b). Using a luciferase reporter, we also showed the p53-
dependent promoter activity of the p53 response element found
in LED exon 2 (Fig. 2f). Altogether, these results demonstrate that
our selected lncRNAs are bona ﬁde p53 targets.
Next, we assessed whether the depletion of our selected p53-
induced lncRNAs phenotypically inﬂuenced the p53 transcrip-
tional response using short interfering RNAs (siRNAs). Among
the investigated candidates, only LED signiﬁcantly inﬂuenced the
G1 checkpoint arrest following nutlin-3a treatment, as shown by
ﬂow cytometry (Fig. 2g,h). To corroborate this ﬁnding, we ﬁrst
evaluated cellular entry into mitosis using phospho-H3 (ser10)
staining. Cells treated with siRNAs targeting LED showed a
signiﬁcant increase of phospho-H3 (ser10) compared with cells
transfected with a non-targeting siRNA (Fig. 2i,j). Furthermore,
cell proliferation assays conﬁrmed this observation, as LED-
suppressed cells proliferated more following nutlin-3a treatment
in comparison with control-transfected cells (Supplementary
Figure 2 | Novel p53-regulated lncRNA LED. (a) Outline of pipeline for identiﬁcation of p53-regulated lncRNAs. MCF-7 cells were treated with 8mM
nutlin-3a for 12 h and subjected to RNA sequencing (RNA-seq). (b) Display of genomic location and RNA-seq data showing the nutlin-3a induction of
selected lncRNAs in MCF-7 cells. Values are represented by RPM (reads per million). (c) Stress-dependent regulation of selected lncRNAs upon nutlin-3a
(8 mM) and ionizing radiation (IR; 10Gy) treatment in MCF-7 cells measured by quantitative reverse transcription–PCR (qRT–PCR). Values are represented
by fold induction (n¼ 3; ***Po0.005, **Po0.01, *Po0.05, two-tailed Student’s t-test). (d) P53-dependent regulation of validated lncRNAs in MCF-7 cells
transfected with a control (Ctrl) or p53 siRNA in the presence or absence of nutlin-3a. Values are represented by fold induction (n¼ 3; **Po0.01, *Po0.05,
two-tailed Student’s t-test). (e) Schematic representation of p53 response element (p53 RE) in LED gene body. Chromatin immunoprecipitation performed
in nutlin-3a-treated MCF-7 cells using IgG or p53 antibodies followed by qPCR in the p53 RE region. Values represent the percentage of input (n¼ 3;
*Po0.05, two-tailed Student’s t-test). (f) MCF-7 cells were co-transfected with an empty or LED (exon 2) p53BS pGL3-basic vector and either a Ctrl or
p53-targeting siRNA. The relative luciferase activities (Fireﬂy/Renilla) were normalized to the Ctrl reaction (empty pGL3-basic vector; n¼ 3; ***Po0.005,
**Po0.01, two-tailed Student’s t-test). (g) qRT–PCR measuring relative LED RNA levels in MCF-7 cells transfected with a Ctrl or two independent LED
siRNAs (LED-kd; n¼ 3; ***Po0.005, *Po0.05, two-tailed Student’s t-test). (h) Relative cell cycle variation (LED-kd minus control-kd) of MCF-7 cells
transfected with a Ctrl or two independent LED siRNAs, treated with nutlin-3a for 12 h. To capture cycling cells in G2/M, cells were treated with nocodazole
for 24 h, before ﬂow cytometric analysis (n¼ 3; **Po0.01, *Po0.05, two-tailed Student’s t-test). (i) Immunostaining detection of the mitotic marker
phospho-histone H3 ser10 (P-H3) and 4,6-diamidino-2-phenylindole (DAPI) staining in MCF-7 cells treated as in h and using a siRNA targeting p21 (p21kd)
as a positive Ctrl. Scale bar, 25mM. (j) Quantiﬁcation of the marker P-H3 from i indicating the percentage of mitotic cells (n¼ 3; *Po0.05, two-tailed
Student’s t-test).
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Fig. 2c,d). Thus, the induction of LED lncRNA is required for
efﬁcient sustenance of p53 transcriptional response.
To investigate the mechanism by which LED impacts the p53
transcriptional response, we performed gene expression analysis
by RNA-seq following knockdown of LED in MCF-7 cells treated
12 h with nutlin-3a. A total of 1,983 genes were responsive to LED
depletion (FDR less than 1%), of which 1,340 were upregulated
and 643 downregulated (Fig. 3a). Interestingly, LED knockdowns
signiﬁcantly reduced the levels of the cell-cycle regulator p21
(FDR of 2.7e-8; Fig. 3b), without inﬂuencing p53 levels (FDR of
0.12). We further validated this observation by showing the LED-
dependent regulation of p21 at both the mRNA (Fig. 3c)
and protein levels (Fig. 3d). Similar results were also obtained
in ZR-75-1 and MALM-3M cell lines (Supplementary Fig. 3).
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Altogether, our results indicate that LED is required
for an efﬁcient p53-dependent checkpoint by maintaining high
levels of p21.
LED associates with and regulates enhancer domains. Next, to
investigate whether LED, a bona ﬁde lncRNA ofB5 kb, exerts its
function in the nucleus or in the cytoplasm, we examined its
subcellular localization (Fig. 4a,b and Supplementary Fig. 4a,b).
As LED is partially located in the nucleus, we set out to assess its
putative interaction with chromatin. We performed chromatin
isolation by RNA puriﬁcation technique (ChIRP)23 using anti-
sense oligos to LED (odd and even) or the bacterial b-
galactosidase (lacZ) and conﬁrmed the speciﬁc enrichment for
LED, but not glyceraldehyde 3-phosphate dehydrogenase RNA
(Supplementary Fig. 4c). Then, we sequenced the DNA fragments
co-puriﬁed in the two pools, aligned reads to the genome and
processed them using peak calling software in a pipeline
developed for ChIRP-seq data. Overlap of the peaks from the
odd and even puriﬁcations indicated LED binding in 1,698
putative sites (Supplementary data 2). To investigate the nature of
the genomic features present at LED-associated domains, we
made use of chromatin state annotations previously deﬁned by
Ernst and colleagues14. Intriguingly, although LED-associated
sites were present in all chromatin states, signiﬁcant enrichment
was observed in strong enhancer regions (Fig. 4c and
Supplementary Fig. 4d). Moreover, intersection with the GRO-
Seq data revealed that a subgroup of LED-bound enhancers was
sensitive to nutlin-3a (Fig. 4d). Interestingly, further analysis
showed that this subgroup was partially overlapping with p53,
STAT3, BCL3 and FOS (Supplementary Fig. 4e). This observation
suggests LED as a co-factor in the nutlin-3a-dependent regulation
of enhancers.
To assess the regulatory potential of LED on enhancers, we ﬁrst
selected a subset of LED-associated enhancer domains
(Supplementary Fig. 4f). Then, we reasserted that bound
enhancers harbour hallmarks of active enhancers3,24,25
(Supplementary Fig. 4g). Furthermore, we performed ChIP for
H3K4me1 and H3K4me3, to conﬁrm the relative deposition of
these histone modiﬁcations in our cell system (Fig. 4e). Next, we
tested a selected group of LED-associated enhancers for eRNA
production by quantitative reverse transcription–PCR; after
DNase-treatment of RNA isolated from MCF-7 cells incubated
with or without nutlin-3a. As previously observed with the GRO-
Seq, this analysis conﬁrmed the nutlin-3a-dependent
transcriptional induction of eRNAs at all tested LED-associated
enhancers (Fig. 4f). This nutlin-3a induction of eRNAs was
speciﬁc, as the abundance of a control, LED-unbound, FOXC1
enhancer (FOXC1e) RNAs remained unaffected. Strikingly, RNA
interference-mediated LED knockdown reduced the level of
activation of these putative eRNAs (Fig. 4g), indicating direct
regulation of eRNA production by LED. Intriguingly, we noticed
among the LED-associated enhancers a prominent peak located
within the ﬁrst intron of p21. We further validated the association
of LED to p21 enhancer (p21e) domain using ChIRP-qPCR
(Supplementary Fig. 4 h). To evaluate the enhancing potential of
p21e, we cloned a 1.2-kb fragment into a pGL3-promoter
luciferase reporter vector. As expected from an enhancer
domain, p21e activated the luciferase gene in an orientation-
independent manner (Fig. 4h). A detailed analysis of p21e 1.2 kb
fragment revealed the presence of a p53 response element
overlapping LED-binding site (Supplementary Fig. 4i). Thus, we
suggested that both LED and p53 may participate in regulating
p21e enhancing activity. Indeed, we demonstrated that LED or
p53 knockdown decreases the enhancing activity of both sense
and antisense p21e luciferase reporters (Fig. 4i). Using northern
blotting and RNAPII ChIP experiments, we further supported the
presence of an antisense eRNA at p21e locus and its regulation by
nutlin-3a and LED (Fig. 4j,k and Supplementary Fig. 4j). Last, we
examined whether p21e could interact with distant promoters by
DNA looping, using circular chromosome conformation capture
(4C) experiments. This analysis failed to reveal long-distance
enhancer–promoter interactions, suggesting that p21e acts within
its functional domain on the p21 promoter (Supplementary
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Figure 3 | LED is required for the proper p53 transcriptional response.
(a) RNA sequencing heatmap showing a subset of genes differentially
expressed upon LED knockdown in MCF-7 cells treated 12 h with nutlin-3a
(only the subset with absolute fold-change430% and FDRo5% is shown).
(b) Barplot derived from the RNA-sequencing showing the normalized p21
mRNA levels in control and LED knockdown conditions. (c) Relative mRNA
levels of p21 upon transfection of a control or two independent LED siRNAs
(LED-kd), measured by qRT–PCR in MCF-7 cells treated with Nutlin-3a for
12h (n¼ 3; *Po0.05, two-tailed Student’s t-test). (d) Western blot showing
p53 and p21 protein levels in MCF-7 cells transfected with a control or two
independent LED siRNAs (LED-kd) and treated with nutlin-3a for 12 h.
Detection of CDK4 protein levels is also displayed.
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Figure 4 | LED binds preferentially to enhancers and regulates enhancer RNA production from p53RERs. (a) LED subcellular localization in MCF-7 cells
treated with nutlin-3a. U2 and S14 genes were used as controls (Ctrl) for nuclear and cytoplasmic fraction, respectively. (b) Northern blot analysis showing
LED transcript in MCF-7 cells incubated or not with nutlin-3a. U6 was used as a loading Ctrl. (c) Enrichment of LED ChIRP peaks in genomic features
deﬁned by ENCODE. (d) Bar graph showing the fraction of induced p53RERs of all found putative enhancer regions (left) and of all LED-bound enhancer
regions (right). The enrichment of induced p53RERs in the LED-bound fraction is signiﬁcant with P¼0.0011 (hypergeometric distribution).
(e) Quantiﬁcation of H3K4me1 and H3K4me3 at LED-associated p53RERs by ChIP-qPCR in MCF-7 cells. Values were corrected to total H3 and MDM2
promoter was used as a Ctrl. Mean±s.d. are shown. (f) Nutlin-3a regulation of LED-associated p53RERs expression in MCF-7 cells. FOXC1e was used as a
negative Ctrl (n¼ 3; ***Po0.005, **Po0.01, *Po0.05, two-tailed Student’s t-test). (g) LED-dependent regulation of p53RERs upon nutlin-3a treatment in
MCF-7 cells transfected with a Ctrl or LED siRNA. FOXC1e was used as a negative Ctrl (n¼ 3; ***Po0.005, **Po0.01, *Po0.05, two-tailed Student’s
t-test). (h) MCF-7 cells were transfected with an empty, p21e-sense or p21e-antisense reporter construct. The ﬁreﬂy/renilla luciferase activities were
normalized to the Ctrl reaction (n¼ 3; ***Po0.005, two-tailed Student’s t-test). (i) MCF-7 cells were co-transfected with an empty, p21e-sense or
p21e-antisense pGL3-promoter vector and either a Ctrl, LED siRNA or p53 siRNA. The relative luciferase activities were normalized to the Ctrl reaction
(empty vector) and subsequently to the Ctrl siRNA (n¼ 3; ***Po0.005, *Po0.05, two-tailed Student’s t-test). (j) Northern blot analysis showing p21e
antisense transcript in MCF-7 cells treated or not with nutlin-3a. 18S was used as a loading Ctrl. (k) Quantiﬁcation of RNAPII binding at p21e and FOXC1e
regions by ChIP-qPCR. MCF-7 cells were transfected with a Ctrl or LED siRNA and treated with nutlin-3a (n¼ 3; *Po0.05, two-tailed Student’s t-test).
(l) Quantiﬁcation of H3K9Ac at p21e and FOXC1e regions by ChIP-qPCR. MCF-7 cells were transfected with a Ctrl or LED siRNA and treated with nutlin-3a.
Values were normalized to total H3 (n¼ 3; **Po0.01, two-tailed Student’s t-test).
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Fig. 4k). Collectively, these results demonstrate that LED
associates with chromatin regions marked as enhancers and
regulates the production of eRNAs.
To further delineate the mode of action by which LED
regulates enhancers, we hypothesized that LED controls enhancer
activity by remodelling the epigenetic state of enhancer domains.
To investigate this possibility, we assessed whether LED
inﬂuences the deposition of active enhancer histone marks, such
as H3K27ac and H3K9ac. ChIP analyses revealed that the levels of
H3K9ac, but not H3K27ac, were decreased at p21 enhancer
domain upon LED knockdown (Fig. 4l and Supplementary
Fig. 4l). Similar results were also obtained with another LED-
associated enhancer (Supplementary Fig. 4m). Interestingly, in
concomitance with H3K9ac reduction, we also noticed a lower
p53-binding afﬁnity at distal and proximal enhancers located
upstream of p21 transcription start site (Supplementary
Fig. 4n,o). These results indicate that LED may inﬂuence the
production of eRNAs, by inﬂuencing the deposition of H3K9ac at
speciﬁc enhancer loci. In addition or as a consequence of its
inﬂuence on H3K9ac, LED may inﬂuence the binding of TFs at or
in the vicinity of enhancer domains.
LED is inactivated by promoter hypermethylation in cancer.
Gene expression comparison analysis suggests not only that LED
is activated by p53, but also that its function is intimately linked
to the transcriptional response of p53. We therefore examined
whether LED is inactivated in cancer. Inspection of the LED
promoter sequence identiﬁed a large CpG island region (Fig. 5a).
As CpG islands are often subject to hypermethylation and
silencing, we asked whether LED promoter hypermethylation
leads to a reduced LED expression in cancers. We ﬁrst measured
the methylation status of LED CpG islands in 135 cancer cell lines
covering a wide range of cancers. Notably, we ﬁnd LED promoter
methylation inB44% (59/135) of all tested cell lines, with a large
proportion in leukaemia (Supplementary Fig. 5a–c). Moreover,
we observed a strong preference for methylation in p53 WT cell
lines (60%; 29/48) as compared with p53 mutants (34%; 30/87,
P¼ 0.004 (w2); Fig. 5a, Table 1). Most importantly, we then
assessed and validated the transcriptional silencing of LED by its
promoter-associated hypermethylation on several cancer cell
lines. As expected, there was a signiﬁcant anti-correlation
between LED expression and its methylation status (Fig. 5b and
Supplementary Fig. 5d,e). Also, treatment of LED-promoter-
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hypermethylated cell lines with the DNA-demethylating agent 5-
Azacytidine resulted in LED re-expression (Fig. 5c). Moreover, we
observed that methylation-dependent inactivation of LED may
delay or reduce the induction of p21 mRNA, as compared with
unmethylated cell lines (Supplementary Fig. 5f). Finally, we
evaluated the prevalence of LED-promoter hypermethylation in
various human tumours. Using methylation-speciﬁc PCR, we
observed LED-promoter hypermethylation in various tumour
types, most prominently reaching 22% of all samples in acute
lymphocytic leukaemia (ALL; Fig. 5d and Table 2).
Discussion
Coordination of gene expression components within response
programmes is a delicate task crucial for the maintenance of
cellular homeostasis. One key player for such coordination is the
tumour-suppressor p53, which organizes the implementation of
an appropriate cellular response to stress cues such as DNA
damage and emerging oncogenes. With the discovery that the
genome is pervasively transcribed26, it is likely that novel p53-
sensitive transcripts and regulatory networks will be uncovered.
Although many target promoters of p53 are well-established, little
is known about the role of this master tumour suppressor as
enhancer factor.
ERNAs were recently suggested as transcriptional regula-
tors9,27. Moreover, eRNA level emerges as robust readout for
determining enhancer activity, as it correlates with the expression
levels of neighbouring target genes. The GRO-seq is a very
powerful technique that can be used to globally measure newly
synthesized eRNAs and to infer enhancer activity in a genome-
wide manner. Here we used GRO-seq to map and quantify
eRNAs induced by the p53 inducer nutlin-3a, and identiﬁed
hundreds of regulated enhancer domains. Although many
enhancers are direct targets of p53, most nutlin-3a-regulated
enhancer domains were not bound by this TF. Thus, it is likely
that those enhancers are bound and inﬂuenced by factors
regulated by p53. In this respect, bioinformatics analyses
revealed three TFs (STAT3, BCL3 and FOS) with potential
regulatory impact on p53-free enhancer regions. However,
despite the potential combined inﬂuence of these three TFs on
approximately 55% of p53FERs, the regulation of a large fraction
remains unexplained. In search of novel p53FER regulators, we
discovered LED, a lncRNA induced by p53, and subsequently
demonstrated its involvement in the regulation of p53-sensitive
enhancers, including both p53BERs and p53FERs. In support of
our ﬁnding, two recent studies reported that not only TFs but also
trans-acting lncRNAs are present at transcriptional regulatory
regions18,19. For instance, the lncRNA Paupar was found to
interact with the TF PAX6 at enhancer domains in order to
modulate the expression of genes involved in neural stem cell fate.
Thus, for the ﬁrst time, we demonstrate the contribution of a
p53-induced lncRNA, termed LED, in the regulation of enhancer-
derived transcripts.
LED is a direct transcriptional target of p53. Suppression of
LED expression attenuated the activation of target enhancer
domains, as demonstrated by reduced eRNA production
and by a lower H3K9 acetylation. We found that LED was
associated with different genomic loci and especially enriched at
enhancer domains producing eRNAs. Notably, a subgroup of
these enhancers is regulated by p53. Moreover, some, but not all,
LED-bound enhancers were concomitantly bound by p53.
Despite this observation, all tested LED-bound p53-induced
eRNAs responded to siRNA-mediated LED depletion. This
suggests that LED is a p53-induced factor that contributes to
both the direct and indirect p53 transcriptional response.
How exactly does LED trigger enhancer activation? Modulation
of the chromatin epigenetic state plays an important role in the
regulation of gene expression. Thus far, several studies have put
forward the idea that lncRNAs are important epigenetic
regulators. For example, the lncRNA HOTAIR represses gene
expression by interacting with and guiding the polycomb
repressive complex 2 to target promoters, where it contributes
to chromatin compaction by catalysing the methylation of
histone H3 at lysine 27 (ref. 28). Alternatively, ribonucleoprotein
complexes such as HOTTIP:MLL/WDR5 activate gene expression
by promoting the deposition of an active mark (H3K4me3)
on promoters29. Here we complement these observations by
showing that LED is essential for the acetylation of H3K9 at
bound enhancers, a modiﬁcation associated with active gene
transcription. Moreover, the p21 locus analysis also revealed the
potential implication of LED in the epigenetic regulation of
nearby contacted enhancers. This ﬁnding is consistent with the
fact that LED is required for proper p53 binding at p21 upstream
enhancers, as well as for RNAPII loading and eRNA transcription
at bound enhancers. Moreover, genome-wide deposition of
H3K9 acetylation was previously reported to be enriched at
regulatory elements such as promoters, enhancers and repetitive
sequences14. Consequently, active transcriptional programmes
may primarily be epigenetically governed by the action of a subset
of activating lncRNAs. However, whether LED inﬂuences the
epigenetic features of regulatory elements before the TF-binding
dysregulation, remains to be elucidated.
P53 is one of the most commonly inactivated gene in human
cancer, with somatic mutations occurring in approximately half
of all human cancers30. In addition, alterations in the p53
pathway often represent an alternative route to attenuate the
function of WT p53 in tumour31,32. Here we demonstrate that
LED lncRNA is largely silenced in p53 WT primary human ALL.
Although our DNA methylation analysis mainly focused on ALL
tumours, it is likely that LED inactivation also occurs in other p53
WT tumours, such as on breast, liver and prostate. Nevertheless,
this important observation pinpoints the dysregulation of
lncRNAs as a potent mechanism in tumorigenesis. In support
of this concept, other lncRNAs have been linked with cancer. For
example, the oncogenic lncRNA HOTAIR is highly expressed in
breast tumours and promotes cancer metastasis by guiding
Table 1 | Association of LED CpG island hypermethylation
with TP53 mutational status in human cancer cell lines.
Methylation TP53 WT TP53 mut
Methylated 29 (60%) 30 (34%)
Unmethylated 19 (40%) 57 (66%)
Total (135) 48 87
LED, LncRNA activator of Enhancer Domains; mut, mutant; WT, wild type.
Table 2 | Frequency of LED promoter associated-
hypermethylation (M) in cancer patients.
Tumour type Methylation Total %
Acute lymphocytic leukaemia 21 95 22
Cutaneous lymphomas 1 6 16
Folicular lymphomas 1 10 10
Melanomas 4 46 9
Acute myeloid leukaemia 1 13 8
Chronic lymphocytic leukaemia 1 33 3
LED, LncRNA activator of Enhancer Domains.
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polycomb repressive complex 2 to speciﬁc genomic loci28. The
lncRNA ANRIL and SChLAP1 are overexpressed in prostate
cancers and antagonize the tumour-suppressive activity of
INK4a/b and SWI/SNF complex, respectively33,34. Finally,
tumour-suppressive lncRNAs such as GAS5 have been shown
to be downregulated in cancer35.
Collectively, our results highlight a novel tumour suppressive
mechanism involving a p53-induced lncRNA acting on enhancers
(Fig. 6). The existence of a crosstalk between different lncRNA
species uncovers an emerging regulatory network with potential
considerable impacts in cancer development.
Methods
Analysis of GRO-seq data and determination of enhancer regions. GRO-seq
protocol was performed as previously described36. Brieﬂy, MCF-7 cells were
incubated with or without 8 mM nutlin-3a for 12 h and 5 million nuclei were
isolated for each condition. rRNA reads were removed from the data by alignment to
a rRNA index compiled from Ensembl annotations (‘rRNA’, ‘rRNA_pseudogene’
and ‘Mt_rRNA’) using bowtie2 (v.2.0.6, parameters ‘—seed 42 —end-to-end -N1 -
L20 -i C,1 -D5 -R5’) and keeping the unmapped reads. GRO-seq data were aligned to
hg19 (including unassembled contigs) using bowtie2 (v. 2.0.6) with parameters ‘—
seed 42 —sensitive’. Alignments with mapping quality lower than 10 and non-
primary alignments were not considered in further analyses. Broad ChromHMM
data for nine cell lines14 were used to screen putative enhancer regions. Along each
chromosome, positions that were marked as enhancer regions (feature IDs 4, 5, 6 and
7) in at least one cell line were merged into regions. Transcription start sites, as
annotated by RefSeq (obtained from the UCSC database server, 9 August 2012) and
GENCODE v19/BASIC were extended by 1,000 bases and used to blacklist positions
(that is, those positions were excluded as putative enhancer regions). Each merged
region was tested for the presence of p300 and Pol2 as determined by ENCODE in
MCF-7 cells (accessions GSM822295 and GSM1010800 (refs 37,38)) and each region
without p300 and Pol2 peak was removed. The remaining regions were considered
putative enhancer regions with enhancer marks. GRO-seq counts were obtained for
each region, after extending each region by 1 kb. Regions having detectable
transcription on both strands were considered putative enhancer regions with
bidirectional transcription and used for downstream analyses. edgeR39 was used to
determine statistical signiﬁcance of differential expression of the enhancer regions
(separately for each strand).
Generation of omnibus annotation. Ensembl annotations (v37.65), RefSeq gene
annotations (obtained from UCSC database server 9 August 2012) and the Broad
Linc RNA catalogue20 were merged in a single GTF (annotation ﬁle) using the
gffread utility supplied with the Cufﬂinks package (v. 1.3.0), using parameters ‘-M -
K -F -G’. This essentially collapses overlapping exons/transcripts so as to create an
omnibus with low degree of redundancy yet high coverage of known and novel
transcripts.
Analysis of RNA-seq data. RNA-seq samples were processed according to
Illumina’s protocol. Raw RNA-seq data were aligned using TopHat2 (v. 2.0.3)40,
using parameters ‘-m1 -p4 -F0.0 —segment-length 21 —segment-mismatches 1’
and an exon annotation GTF ﬁle that was generated as described before. Reads
with mapping quality less than 10 and non-primary alignments were discarded.
Remaining reads were counted using HTSeq-count (http://www-huber.embl.de/
users/anders/HTSeq/doc/overview.html), per gene ID. Statistical analysis of the
differential expression of genes was performed using edgeR39. Genes with False
Discovery Rate (FDR) for differential expression lower than 0.01 were considered
signiﬁcant.
Analysis of p53 ChIP data. p53 ChIP-seq data obtained from MCF-7 cells upon
untreated and p53-stimulated conditions were obtained from SRA project
SRP007261. Alignment was done using bowtie2 (v. 2.0.6) with parameters ‘
—seed 42 —sensitive’ to hg19 (including unassembled contigs). Only primary
alignments with quality of at least ten were kept. Peaks were called by
MACS (v. 2.0.10.20130501) using default parameters. Peaks with a fold-change
(w.r.t. input) lower than 3.0 or a -log10(q-value) lower than 2.0 were discarded.
Sequence motif enrichment analysis. For enhancer regions the midpoint of
bidirectional transcription was established, after pooling the GRO-seq data of the
nutlin-3a-treated replicates. Two hundred bases of DNA around the midpoint of
bidirectional transcription were extracted. For the analysis of sequence enrichment
of BERs and FERs, the backgrounds were enhancers with bidirectional transcrip-
tion that had an FDR for differential expression of 0.75 or greater (for both
strands). In addition, for FERs the background contained only enhancers that had
no p53 peak within 1 kb. HOMER17 was used to search for overrepresented
sequence motifs, using parameters ‘-nogo -nlen 4 -len 18 -S 5 -mis 2’.
Constructs. p21e domain sense and antisense were PCR ampliﬁed using gDNA
derived from MCF-7 cell lines and subsequently cloned (Nhe1/Xho1) into pGL3-
promoter luciferase reporter vector. All primers used are listed in Supplementary
table 1.
Cell culture and transfection. MCF-7 cells were cultured in DMEM containing
10% FBS, penicillin and streptomycin at 37 C and 5% CO2. Identiﬁcation and
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Figure 6 | Schematic representation of LED function in normal and cancer cells. P53-bound enhancer regions (p53BERs), p53-free enhancer regions
(p53FERs) and H3K9 acetylation are displayed.
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validation of lncRNA regulated by nutlin-3a were carried out by treating MCF-7
cells with 2–8 mM of nutlin-3a for a period of 4–12 h. To induce a p53 stress-
response, cells were also treated with 10Gy of ionizing radiation for 12 h. RNA
interference experiments were performed using Dharmafect transfection reagent-1
and between 20 and 60 nM of siRNA. For epigenetic study, cells were treated with
2 mM 5-aza-20-deoxycytidine (A3656, Sigma) for 72 h.
Protein analysis. Whole-cell lysates were prepared as previously described31.
Protein detection was performed using primary antibodies detecting p53 (DO1,
Santa Cruz, 1:1,000), p21 (Sc-397, Santa Cruz, 1:1,000), CDK4 (Sc-260, Santa Cruz,
1:1,000), phospho-histone H3 (ser 10) (9701, Cell Signaling, 1:100). Proteins were
visualized using adequate secondary antibody (Dako) and ECL reagents (GE
Healthcare).
Quantitative real-time PCR. RNA isolation and cDNA preparation were carried
out as previously described9. Real-time qPCR analysis was performed using the
LightCycler 480 SYBR Green I Master mix (Roche). The glyceraldehyde 3-
phosphate dehydrogenase was used as an internal control.
Flow cytometry. Control or nutlin-3a-treated cells were arrested in mitosis using
250 ngml 1 of nocodazole for 24–36 h. Cells were then trypsinized, washed and
resuspended in PBS containing 0.6% NP-40, 50mgml 1 RNaseA and 50mgml 1
propidium iodide for 10min. Cell cycle proﬁles were captured using FACSCalibur
(BD Biosciences) and analysed with the Flowjo software.
Immunoﬂuorescence. Cells were ﬁrst plated at a density of 3 105 cells per well
and concomitantly reverse transfected with a control siRNA or siRNAs against
LED or p21. After 24 h, cells were trypsinized and seeded on microscope coverslips
coated with polylysine. Next, cells were ﬁxed with 3% formaldehyde and subse-
quently permeabilized with PBS-Triton X-100 (0.3%) solution. After blocking 1 h
with 2% PBS-Milk, cells were successively incubated with the primary antibody
phospho-histone H3 (ser 10) and the Alexa Fluor 488 Dye-conjugated secondary
antibody. Images were captured using an AxioCam MRc CCD camera (Carl Zeiss
Microimaging).
RNA ﬂuorescence in situ hybridization. MCF-7 cells treated with nutlin-3a
(8mM) and non-treated controls were grown on coverslips in six-well plates
overnight. The media were aspirated and cells washed 3 in cold PBS. Fixation
solution (5ml of 10 PBS, 5ml of 37% formaldehyde (100% formalin) and 40ml
of Diethylpyrocarbonate (DEPC) treated H2O) was added and cells were incubated
for 20min at 4 C. Cells were washed 3 in cold PBS and 70% cold ethanol was
used to permeabilize cells at 4 C for 24 h. Cells were washed with cold PBS and left
in hybridization buffer (1 g of dextran sulfate, 7ml of DEPC water, 1ml of for-
mamide and 1ml of 20 SSC buffer) for 1 h. A measure of 50 ng of stellaris probe
were used in hybridization buffer and cells were kept incubating for 48 h at 37 C.
After washing with wash SSC buffer, coverslips were covered with Draq5 during
20min for nuclear staining, washed with cold PBS and mounted using antifade
buffer (850 ml of DEPC H2O, 100ml of 20 SSC, 40 ml of 10% glucose, 10 ml of
Tris). Images were captured in a Zeiss confocal microscope.
ChIRP. ChIRP was performed as previously described41. ChIRP probes (48 40-
mer) targeting LED and lacZ were designed at http://www.singlemoleculeﬁsh.
com/designer.html. Probes antisense to LED were divided into two sets (odd and
even). The input and odd and even probe samples were sequenced individually.
After clipping of adapters from the obtained reads, data were aligned to hg19 using
bowtie2 (v. 2.0.6) using parameters ‘—seed 42 -N 1 -p 2’. Reads with mapping
quality less than 10 and non-primary alignments were excluded from further
analysis. Peak detection was run using MACS (v. 2.0.10.20130501)42 using
parameters ‘ -g hs -B -p 0.1’. Peaks with a  log10(q-value)Z5 and an enrichment
Z4 with respect to the input were kept, and peaks found in the odd and even
samples were intersected. Overlapping peaks in both samples that had a position-
wise Pearson correlation of abundanceZ0.2 and at least 25 reads in both samples
were merged. From the resulting set of peaks, plasmid contaminants were
discarded (Supplementary Table 2).
ChIP. MCF-7 (5 106) cells were ﬁrst transfected with a control or speciﬁc siR-
NAs. Next, cells were ﬁxed with 1% formaldehyde for 8min at room temperature
and subsequently quenched with 125mM glycine for 5min on ice. The cells were
pelleted 10min at 470 g and re-suspended in 300 ml of cold lysis buffer (50mM
Tris-HCl, pH 8.0, 10mM EDTA and 1% SDS) supplemented with protease inhi-
bitor cocktail (Roche). The suspension was sonicated 20min (30 s on/off at max-
imum power) and further diluted with 800ml of dilution buffer (10mM Tris-HCl,
pH 7.5, 140mM NaCl, 1mM EDTA, 0,5mM EGTA and 1% Triton X-100) sup-
plemented with protease inhibitor cocktail. The lysate was centrifuged for 10min at
maximum speed and the soluble fraction (chromatin) was transferred to a new
tube. For each ChIP reaction, 100 ml of chromatin preparation was diluted with
300ml of dilution buffer and incubated on an end-to-end rotator with 2–10 mg of
antibody at 4 C overnight. Then, 30 ml of protein A/G beads, previously blocked
1 h with PBS/BSA (0.1%) solution, was add to each ChIP reaction and incubated 2–
3 h at 4 C. The immune-puriﬁed chromatin was washed 2 5min with the
dilution buffer and 1with TE (50mM Tris-HCl pH 8.0 and 10mM EDTA) and
ﬁnally eluted in 300 ml elution buffer (20mM Tris-HCl pH 7.5, 5mM EDTA,
50mM NaCl and 1% SDS) at 65 C overnight. Eluted chromatin was puriﬁed using
QIAquick PCR puriﬁcation kit (Qiagen) and subjected to real-time PCR analysis.
Antibodies and amounts used in this study were as follows: pol2 (8 mg, CTD4H8,
Upstate), H3K9ac (3 ml, ab4441, Abcam), H3K27ac (3 ml, ab4729, Abcam),
H3K4me1 (6 ml, ab8895, Abcam), H3K4me3 (3ml, MC315, Upstate), histone H3
(5 ml, 2650, Cell Signaling).
Chromosome conformation capture on chip (4C). 4C templates preparation and
analysis were performed as previously described43. Brieﬂy, 107 of MCF-7 cells were
harvested and crosslinked with formaldehyde 2% for 10min at room temperature,
and neutralized with 125M glycine. After washing with PBS, cells were lysed in
150mM NaCl, 50mM Tris-HCl (ph 7.5), 5mM EDTA, 0.5% NP40, 1% Triton
X-100 and nuclei were recovered by spinning 8min at 600 g. Nuclei were digested
overnight with 400U DpnII (NEB) and Csp6I (NEB) and re-ligated in 7ml with
100U of T4 DNA ligase (Roche) overnight at 16 C. Puriﬁed DNA circles were
digested with 50U of DpnII (Csp6I circles) and Csp6I (DpnII circles) overnight at
37 C, followed by heat inactivation and ligation in 14ml with 200U of T4 DNA
ligase. The 4C template was then puriﬁed and used for PCR ampliﬁcation.
DNA methylation analysis. The Methyl Primer Express v1.0 software was used to
identify the CpG islands and design-speciﬁc primers for the methylation analysis
(Supplementary table 1). DNA methylation status was established by bisulﬁte
genomic sequencing of multiple clones or methylation-speciﬁc PCRs in DNA
samples previously treated with sodium bisulﬁte (EZ DNA methylation Gold kit,
Zymo Research). The Illumina 450K methylation array was used to anlyse the
methylation status in multiple human cancer cell lines. For epigenetic drug treat-
ments, cells were treated with 1 mM 5-aza-20-deoxycytidine (Sigma) for 72 h.
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